Individualization of immunosuppression: Concepts and rationale

Current Opinion in Organ Transplantation

Volumn 13, Issue 6, 2008, Pages 604-608

  Wavamunno, Moses D ^a   Chapman, Jeremy R ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Immunosuppression; Pharmacogenetics; Pharmacogenomics

Indexed keywords

CALCINEURIN INHIBITOR; CARRIER PROTEIN; CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; DRUG METABOLIZING ENZYME; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; PROTEIN KINASE;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DOSE CALCULATION; DRUG ANTAGONISM; GENETICS; GENOTYPE; METABOLISM; METHODOLOGY; ORGAN TRANSPLANTATION; PHENOTYPE;

ANIMALS; CALCINEURIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; GENOTYPE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE TRANSPORT PROTEINS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASES;

EID: 60849086797     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283193bc5     Document Type: Review

References (43)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
2. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrol Dial Transplant 2006; 21:2060-2063.
3. Vercauteren SB, Bosmans JL, Elseviers MM, et al. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int 1998; 54:536-545.
4. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68:55-62.
5. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr postdose levels (C2). Transplantation 2002; 73:953-959.
6. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73 (9 Suppl):S12-S18.
7. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76:903-908.
8. Midtvedt K, Fauchald P, Bergan S, et al. C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003; 76:1236-1238.
9. Einecke G, Mai I, Fritsche L, et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 2004; 19:215-222.
10. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18 (Suppl 1):i12-i15.
11. Chisholm MA, Middleton MD. Modified-release tacrolimus. Ann Pharmacother 2006; 40:270-275.
12. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321-1325.
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029-1037.
14. Sollinger HW. Mycophenolate mofetil. Kidney Int Suppl 1995; 52:S14-S17.
15. Pawinski T, Durlik M, Szlaska I, et al. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months posttransplant. J Clin Pharm Ther 2006; 31:27-34.
16. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3:534-542.
17. van GelderT,Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28:145-154.
18. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72:1181-1193.
19. KovarikJM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004; 26:499-505.
20. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233-1235.
21. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82:711-725.
22. Ng FL, Holt DW, MacPhee IA. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother 2007; 8:2045-2058.
23. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 2004; 78:311-315.
24. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/ pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45:1135-1148.
25. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006; 80:51-60.
26. Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008; 29:1-5.
27. Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81:228-234.
28. Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007; 17:321-330.
29. Levesque E, Delage R, Benoit-BiancamanoMO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007; 81:392-400.
30. Kagaya H, Inoue K, Miura M, et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63:279-288.
31. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46:13-58.
32. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14:501-515.
33. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005; 78:351-361.
34. Baldelli S, Merlini S, Perico N, et al. C-440T/T-331 C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007; 8:1127-1141.
35. Formea CM, Myers-Huentelman H, Wu R, et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transplant 2004; 4:1810-1817.
36. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
37. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
38. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-1511.
39. Brogan IJ, Pravica V, Hutchinson IV. Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transpl Immunol 2000; 8:139-141.
40. Gerber DJ, Hall D, Miyakawa T, et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 2003; 100:8993-8998.
41. Tang W, Arnett DK, Devereux RB, et al. Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy. Am Heart J 2005; 150:845-851.
42. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and associa-tion with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008; 83:711-717.
43. Vannozzi F, Filipponi F, Di Paolo A, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004; 36: 2787-2790.